about
Degradation of high-molar-mass hyaluronan by an oxidative system comprising ascorbate, Cu(II), and hydrogen peroxide: inhibitory action of antiinflammatory drugs--naproxen and acetylsalicylic acidHuman osteoarthritic chondrocytes exposed to extremely low-frequency electromagnetic fields (ELF) and therapeutic application of musically modulated electromagnetic fields (TAMMEF) systems: a comparative study.Advances in chondroitin sulfate analysis: application in physiological and pathological States of connective tissue and during pharmacological treatment of osteoarthritis.Electrophoretic approaches to the analysis of complex polysaccharides.Pharmacological read-through of nonsense ARSB mutations as a potential therapeutic approach for mucopolysaccharidosis VIAnalytical aspects of pharmaceutical grade chondroitin sulfates.Quality of different chondroitin sulfate preparations in relation to their therapeutic activity.Glycosaminoglycan composition of the large freshwater mollusc bivalve Anodonta anodonta.Isolation and characterization of a heparin with high anticoagulant activity from the clam Tapes phylippinarum: evidence for the presence of a high content of antithrombin III binding site.Human milk glycosaminoglycans: the state of the art and future perspectives.Quantitative capillary electrophoresis determination of oversulfated chondroitin sulfate as a contaminant in heparin preparations.Evaluation of chondroitin sulfate bioactivity in hippocampal neurones and the astrocyte cell line U373: influence of position of sulfate groups and charge density.Effects of glycosaminoglycans on U-937 leukemia cell proliferation and differentiation: structure-function relationship.Effects of chondroitin sulfates with different structures on leukemia cells: U-937 cell proliferation and differentiation.Mass spectrometry for the characterization of unsulfated chondroitin oligosaccharides from 2-mers to 16-mers. Comparison with hyaluronic acid oligomers.Activity of chondroitin ABC lyase on dermatan sulfate partially degraded by cupric-ion-mediated free-radical treatment.The genome of the lepidopteran Mamestra brassicae has a vertebrate-like content of methyl-cytosine.Localization and expression of CHST6 and keratan sulfate proteoglycans in the human cornea.Separation of keratan-sulfate-derived disaccharides by high-performance liquid chromatography and postcolumn derivatization with 2-cyanoacetamide and fluorimetric detection.Effect of 6 years of enzyme replacement therapy on plasma and urine glycosaminoglycans in attenuated MPS I patients.About oral absorption and human pharmacokinetics of chondroitin sulfate.Comparison of cetylpyridinium chloride and cetyltrimethylammonium bromide extractive procedures for quantification and characterization of human urinary glycosaminoglycans.Determination of molecular mass values of chondroitin sulfates by fluorophore-assisted carbohydrate electrophoresis (FACE).High-performance liquid chromatography and on-line mass spectrometry detection for the analysis of chondroitin sulfates/hyaluronan disaccharides derivatized with 2-aminoacridone.Composition and structure elucidation of human milk glycosaminoglycans.Structural behavior of highly concentrated hyaluronan.Influence of charge density, sulfate group position and molecular mass on adsorption of chondroitin sulfate onto coral.Selective removal of keratan sulfate in chondroitin sulfate samples by sequential precipitation with ethanol.Oral bioavailability of chondroitin sulfate (Condrosulf) and its constituents in healthy male volunteers.Glycosaminoglycan blotting on nitrocellulose membranes treated with cetylpyridinium chloride after agarose-gel electrophoretic separation.Novel reverse-phase ion pair-high performance liquid chromatography separation of heparin, heparan sulfate and low molecular weight-heparins disaccharides and oligosaccharides.Detection of submicrogram quantities of glycosaminoglycans on agarose gels by sequential staining with toluidine blue and Stains-All.Separation of capsular polysaccharide K4 and defructosylated K4 derived disaccharides by high-performance capillary electrophoresis and high-performance liquid chromatography.Milligram-scale preparation and purification of oligosaccharides of defined length possessing the structure of chondroitin from defructosylated capsular polysaccharide K4.Direct and specific recognition of glycosaminoglycans by antibodies after their separation by agarose gel electrophoresis and blotting on cetylpyridinium chloride-treated nitrocellulose membranes.Oral absorption and bioavailability of ichthyic origin chondroitin sulfate in healthy male volunteers.Separation of Escherichia coli 055:B5 lipopolysaccharide and detoxified lipopolysaccharide by high-performance capillary electrophoresis.Detection of submicrogram quantities of Escherichia coli lipopolysaccharides by agarose-gel electrophoresis.Mild mental retardation and low levels of urinary heparan sulfate in a patient with the attenuated phenotype of mucopolysaccharidosis type IIIA.Plasmatic dermatan sulfate and chondroitin sulfate determination in mucopolysaccharidoses.
P50
Q28212745-3259764C-F7EF-4A81-BC18-5FF0B9FCACCBQ30558532-BF71DCC6-5E71-4A08-81E2-181BC4FD4BFDQ36393625-899D5E0C-B07A-4833-A59A-C1E9235A825CQ36418606-DCAD1003-3A27-4B24-B2A3-C2D6E4501346Q36662823-2C05F2D2-6D34-432B-98BA-6E8066C7D43AQ36881374-8B69F8FE-1FFE-4186-8428-4AE720B733CDQ37611121-7D309895-3610-4ECD-9288-DD26F3F1A7D3Q38318909-3A96154C-A2D6-448F-A5DE-38AB2E82F953Q38338932-1992F686-345D-46A7-94C6-D9567052E4C2Q39485138-CC1D1EF5-EB00-453B-BC7C-C32F32EF26A9Q39861279-1126BFD7-EAF3-4D02-B61A-27DE3445B3D6Q40466618-EEAB9086-3C8D-40BE-B071-23B93AD579D3Q41431042-5ED53F09-D3E2-437C-8877-FB90EB61D8D4Q41532429-EE1DFBC1-A2AB-4D32-9EA0-A2645BBE6490Q41595190-052C3ADB-5C14-40B6-953B-842B41E7B6E0Q41671288-97123C51-5339-4435-BA0F-CE461B5F3541Q42046115-3FFD6159-8F18-4C25-9981-4D2DA24EA75DQ42472696-9BFEF968-3CF6-42D1-B7FC-EAD2CAED74A9Q42813035-10CE7213-DFBF-4129-8080-FDD572BA51B3Q43031314-B59571A2-41A8-4B8E-8D78-0A7642769F93Q43051046-4DD96245-DE56-4D81-A944-F960D060FA9BQ43074687-C3179E4B-641F-46F4-83EE-0B12FD006172Q43237336-D62DD1CB-5A1B-49F1-93FD-A2E223562E7FQ43273475-35F77676-9601-4EB0-88DF-434970481E05Q43411144-95DB0E11-EA13-43E2-B53F-8E6E13F1B767Q43646147-B57B3F24-BCCB-4253-921C-ED470BAA3236Q44031233-BA140C57-00F0-40EB-8550-C94C5786A720Q44038764-37C8365B-CB8D-400A-A753-681D04A868E7Q44163866-F9E81EF7-D0D5-418A-A8EA-24074874979EQ44175288-423725BF-6B26-41A4-A9A8-8093F8EBC61CQ44247922-5BA756F2-999C-4A42-B3A9-9210E0E6FE08Q44248466-688F7161-0C1D-46D8-A3F4-85C120CD5142Q44377481-3454F31B-DBD5-4E0A-B803-E3053DB34BA4Q44408473-1E59A1A4-8184-418B-B09B-A8C734A37A85Q44429907-875E9614-F67B-46E9-AE60-1D676F644CDCQ44474736-46B3792B-E902-443A-B3CA-7AA221824E7BQ44584642-E878ED4B-FB48-44EC-89C3-277DFE30A745Q44641363-AC9C15B5-0109-4C9E-B1B3-DB7299C5D26EQ44666464-94A85DF0-321F-4D0A-A2D8-881DC46B0E07Q44684181-76DE9309-1C0C-4F9F-8200-60C7FF3E70A6
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Nicola Volpi
@ast
Nicola Volpi
@en
Nicola Volpi
@es
Nicola Volpi
@nl
Nicola Volpi
@sl
type
label
Nicola Volpi
@ast
Nicola Volpi
@en
Nicola Volpi
@es
Nicola Volpi
@nl
Nicola Volpi
@sl
prefLabel
Nicola Volpi
@ast
Nicola Volpi
@en
Nicola Volpi
@es
Nicola Volpi
@nl
Nicola Volpi
@sl
P1053
D-4874-2015
P106
P1153
7005703624
P21
P31
P3829
P496
0000-0002-0749-6104